

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1- 46 (canceled).

47. (New) A method of treating or preventing a disease or disorder in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of enantiomerically pure (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide, or a pharmaceutically acceptable salt or solvate thereof, wherein the disease or disorder is epidemic keratoconjunctivitis, atopic keratitis, superior limbic keratitis, polyarteritis, Scleritis, chronic uveitis, chronic vitritis, retinitis, choroiditis, pars planitis, sclerosing cholangitis, rubeosis, periodontitis, or gingivitis.

48. (New) The method of claim 47 wherein the patient is a mammal.

49. (New) The method of claim 47 wherein the enantiomerically pure (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide is administered parenterally, transdermally, mucosally, nasally, buccally, sublingually, topically or orally.

50. (New) The method of claim 49 wherein the therapeutically or prophylactically effective amount is from about 1 mg to about 5,000 mg per day.

51. (New) The method of claim 50 wherein the therapeutically or prophylactically effective amount is from about 10 mg to about 2,500 mg per day.

52. (New) The method of claim 51 wherein the therapeutically or prophylactically effective amount is from about 100 mg to about 1,200 mg per day.

53. (New) The method of claim 49 wherein the oral administration is in the form of a tablet, a caplet, a capsule, or liquid.

54. (New) The method of claim 49 wherein the enantiomerically pure (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide is administered in a controlled or delayed release dosage form.

55. (New) The method of claim 49 wherein the parenteral administration is by the route of subcutaneous, intravenous, intramuscular, or intraarterial administration.

56. (New) The method of claim 49 wherein the transdermal, topical, or mucosal administration is in the form of ophthalmic solution, spray, aerosol, cream, lotion, ointment, gel, solution, emulsion, or suspension.

57. (New) The method of claim 47, which further comprises administering a therapeutically or prophylactically effective amount of a second therapeutic agent.

58. (New) The method of claim 57 wherein the second therapeutic agent is an anti-cancer drug, an anti-cancer vaccine, an anti-inflammatory drug, an antihistamine or a decongestant.